Webinar 3: Estimands from trial planning to publication in medical journals: The ETHOS trial
19th November 2023 3-4:30 pm UK /4-5:30pm CET/10-11:30am EST/7-8:30am Pacific time

This webinar is free to attend. Click [here](#) to register, and then you will receive details to log into the webinar.

Description: Building on the previous webinar series, we will present a refresher on the key elements of the estimand framework and use the ETHOS trial (NCT02465567) to illustrate the estimand framework and to highlight the different options that may be of interest to different stakeholders. The background and disease context of the case will be described, the important events (termed intercurrent events) occurring in the trial will be described and three estimands will be showcased. It will then be explored how best to communicate the estimands in medical journals.

Topics of discussion will be raised at different points during the training and there will be time allowed (30 mins) to answer your questions, which can be posted via the chat. Questions on how estimands and their corresponding results should be communicated in medical journals, and how to encourage their inclusion in journal articles are particularly encouraged.

The targeted learning outcomes are as follows:

- Understand different estimand strategies that could be of interest in trials in Chronic Obstructive Pulmonary Disease (COPD).
- Recognize the benefits of following the estimand framework (ICH E9 (R1) addendum) in the context of COPD, in order to:
  - frame questions which may be of interest to different stakeholders
  - be transparent when communicating trial results

Target audience: clinicians, regulators, investigators, academics, members of Ethics Committees, statisticians, medical writers, referees and editors of medical journals

Presenters: David Wright¹, Head of Statistical Innovation (AstraZeneca) and Paul Dorinsky², Global Clinical Head (AstraZeneca)

Hosted by the Estimands Implementation Working Group (EIWG) and PSI on behalf of EFSPi and EFPIA.

Link to the paper: [Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD](https://www.nejm.org/doi/full/10.1056/NEJMc2308760) / NEJM.

Link to previous webinars: PIONEERING Estimands in Clinical Development, Estimands in Oncology – How and Why

1 Data Science & Artificial Intelligence, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK
2 Late R&I, BioPharmaceuticals R&D, AstraZeneca, Durham, US